Royalty Pharma (RPRX) has had the highest return since January 1, 2025 by a US stock in the Pharmaceuticals Industry with a market cap of $10B+, returning 29.6%.
| ASSET | % RETURN |
|---|---|
Royalty Pharma (RPRX) | 29.58% |
Novartis AG ADR (NVS) | 21.43% |
GlaxoSmithKline PLC ADR (GSK) | 16.38% |
Takeda Pharmaceutical Co Ltd ADR (TAK) | 16.06% |
Sanofi ADR (SNY) | 14.74% |
AstraZeneca PLC ADR (AZN) | 11.28% |
Johnson & Johnson (JNJ) | 8.36% |
Eli Lilly and (LLY) | 5.69% |
Zoetis (ZTS) | -3.89% |
Pfizer (PFE) | -8.04% |
Bristol-Myers Squibb (BMY) | -9.22% |
Dr Reddy’s Laboratories Ltd ADR (RDY) | -11.05% |
Merck (MRK) | -16.34% |
Novo Nordisk A-S (NVO) | -19.98% |
Teva Pharma Industries Ltd ADR (TEVA) | -26.51% |
Viatris (VTRS) | -29.48% |
